Country: United States
Language: English
Source: NLM (National Library of Medicine)
METOPROLOL TARTRATE (UNII: W5S57Y3A5L) (METOPROLOL - UNII:GEB06NHM23)
Ranbaxy Pharmaceuticals Inc.
METOPROLOL TARTRATE
METOPROLOL TARTRATE 25 mg
ORAL
PRESCRIPTION DRUG
Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate is indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol tartrate. Oral metoprolol tartrate therapy can be initiated after intravenous metoprolol tartrate therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS). Hypertension and Angina Metoprolol tartrate is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see WARNINGS). Hypersensitivity to metoprolol tartrate and related d
Metoprolol tartrate tablets, USP 25 mg are available as white to off-white, round, film-coated tablets, debossed with "RE " above the bisect and "79 " below the bisect on one side and plain on the other side. Bottles of 10 NDC 63304-579-03 Bottles of 100 NDC 63304-579-01 Bottles of 1000 NDC 63304-579-10 Metoprolol tartrate tablets, USP 50 mg are available as pink colored, round, film-coated tablets debossed with "RE " above the bisect and "75 " below the bisect on one side and plain on the other side. Bottles of 10 NDC 63304-580-03 Bottles of 100 NDC 63304-580-01 Bottles of 1000 NDC 63304-580-10 Metoprolol tartrate tablets, USP 100 mg are available as white to off-white, round, film-coated tablets, debossed with "RE " above the bisect and "76 " below the bisect on one side and plain on the other side. Bottles of 10 NDC 63304-581-03 Bottles of 100 NDC 63304-581-01 Bottles of 1000 NDC 63304-581-10 Store at 20 - 25°C (68 - 77°F) [See USP Controlled Room Temperature]. Protect from moisture and heat. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. You may report side effects to FDA at 1-800-FDA 1088.
Abbreviated New Drug Application
METOPROLOL TARTRATE- METOPROLOL TARTRATE TABLET, FILM COATED RANBAXY PHARMACEUTICALS INC. ---------- METOPROLOL TARTRATE TABLETS,USP RX ONLY PRESCRIBING INFORMATION DESCRIPTION Metoprolol tartrate, USP is a selective beta -adrenoreceptor blocking agent, available as 25, 50 and 100 mg tablets for oral administration. Metoprolol tartrate is (±)-1-(isopropylamino)-3-[_p_-(2- methoxyethyl)phenoxy]-2-propanol (2:1) _dextro_-tartrate salt, and its structural formula is Metoprolol tartrate, USP is a white, practically odorless, crystalline powder with a molecular weight of 684.81. It is very soluble in water; freely soluble in methylene chloride, in chloroform, and in alcohol; slightly soluble in acetone; and insoluble in ether. Each tablet for oral administration contains 25 mg, 50 mg or 100 mg of metoprolol tartrate USP and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose anhydrous, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, polyethylene glycol, pregelatinized starch, titanium dioxide. In addition the 25 MG and 100 MG tablet contain propylene glycol and sodium lauryl sulfate; the 50 MG tablet contains D&C Red #30 and talc. CLINICAL PHARMACOLOGY _Mechanism of Action:_ Metoprolol tartrate is a beta -selective (cardioselective) adrenergic receptor blocker. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol tartrate also inhibits beta -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Clinical pharmacology studies have demonstrated the beta-blocking activity of metoprolol, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. _Hypertension_ The mechanism of the antihypertensive effects of beta-blocking agents has not been fully elucidated. However, several possible mecha Read the complete document